Eric Siemers
CMO Acumen Pharmaceuticals
Seminars
Wednesday 4th February 2026
Sabirnetug (ACU193) Case Study: A Next-Generation Anti-Aβ Oligomer Antibody Advancing Disease-Modifying Claims with Translational Biomarker Evidence in Alzheimer’s Therapeutics
11:00 am
- ACU193 selectively targets soluble amyloid-β oligomers (AβOs), sparing monomers and plaques, minimizing the risk of ARIA while preserving synaptic function
- Enhance safety profiles and therapeutic potential for early Alzheimer’s intervention
- Demonstrated CSF biomarker effects in INTERCEPTAD Phase 1 trial (β p tau181, β Aβ42/40 ratio), validating downstream impact on tau pathology and synaptic markers
- Exploring the ongoing ALTITUDE-AD Phase 2 trial with robust biomarker and cognitive endpoints, designed to confirm mechanistic action and clinical efficacy in early AD, and the implications of this for regulatory success and meaningful patient outcomes
Wednesday 4th February 2026
Roundtable Discussion: Is Biomarker‑Only “Preclinical Alzheimer’s” a Disease Stage or a Risk Flag
2:00 pm
- Comparing FDA/Alzheimer’s Association staging versus the International Working Group’s “risk‑only” view, unifying language for target‑discovery teams so translational models match the biology regulators will ultimately judge
- Exploring how the ongoing pre‑symptomatic Donanemab and Lecanemab studies will read out time‑to‑symptoms data, supplying hard evidence on early intervention that can recalibrate animal‑model endpoints and biomarker cut‑offs before the next IND
- Weighing the risk‑benefit of treating asymptomatic, amyloid‑positive individuals given ARIA and payer concerns, clarifying safety and economics thresholds that determine which pre‑clinical candidates advance and at what dose
